---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-049454"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T05:43:52.772530+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics Q1 net income $76.6M on BMS termination revenue; CNTY-101 dosing started

## Summary
- Net income of $76.6M vs $28.1M loss in Q1 2024, driven by $109.2M collaboration revenue from BMS deal termination.
- Cash, equivalents, and securities $185.8M as of March 31, 2025, down from $220.1M; estimated runway into Q4 2026.
- First patient dosed in Phase 1 CALiPSO-1 trial of CNTY-101 for autoimmune disease; clinical data expected by end of 2025.
- CNTY-308 (CD19-targeted CAR-iT) on track to enter IND-enabling studies mid-2025.
- R&D expenses increased to $26.6M from $23.4M due to clinical trial costs and preclinical program advancement.

## SEC filing metadata
- accession: 0001104659-25-049454
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465925049454/0001104659-25-049454-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465925049454/tm2514971d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-049454
- JSON: https://secwatch.observer/filing/0001104659-25-049454.json
- Plain text: https://secwatch.observer/filing/0001104659-25-049454.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.